Insider buying last 90 days
$1.67Min 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 10 | Kenneth L. Cornick Director | Purchase | $1.21M |
| Aug 10 | Kenneth L. Cornick Director | Purchase | $463K |
From Form 4 filings, dated to when each was filed.
NYSE: CLVT
Clarivate (CLVT) Stock Analysis & Forecast
Oct 12 close
$1.610.00 (0.0%)
Gekko Brief
AI summaryOct 12 closeClarivate's week centers on the completed sale of its Life Sciences & Healthcare segment to Altaris, LLC for $600 million, with $500 million in cash received at closing. The deal, which closed on 6 October 2026, is described as a key step in refocusing the company on its Academia & Government and Intellectual Property businesses, with proceeds aimed at reducing debt. Related coverage notes the termination of Henry Levy's role as President of the divested unit and his continuation as CEO of LS&H as it now operates independently, as well as a tax-related share surrender tied to RSU vesting.
The stock closed at $1.61, below both its 50-day average of $1.87 and its 200-day average of $2.34, with the 50-day also under the 200-day. Shares are down 13.9% over one month, 30.6% over three months and 55.4% over one year. The GekkoIndex reads 64.3, placing it in the Accumulation zone, down 11.5 over the past five readings. Gekko Fair Value stands at $2.30, putting the current price 30% below that level.
Clarivate's next earnings report is scheduled for 3 November 2026, before the open, falling within a typical 20-trading-day holding window; the prior report on 29 July 2026 produced a -16.3% reaction despite an EPS beat. Over the last 90 days, 2 open-market insider purchases totaling $1,671,500 have been recorded. Seasonally, the next 20 trading days have averaged -1.8% across 5 years, with gains in 3 of them. Analyst views span 1 buy, 3 hold and 1 sell among 5 firms, with a consensus target of $2.97.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Clarivate price vs fair value
Close $1.61200-day averageGekko Fair Value $2.30
Clarivate quick facts
- Market cap
- $1.03B
- P/E ratio
- —
- Forward P/E
- 2.6
- EPS, TTM
- −$0.52
- Revenue, TTM
- $2.41B
- Profit margin
- -13.8%
- Dividend yield
- —
- Beta
- 1.40
- Volume
- 2.04M avg 4.15M
- 1-year return
- −55.4%
- Typical daily move
- ±5.7%
- Typical 20-day move
- ±9.1%
- 50-day average
- $1.87
- 200-day average
- $2.34
- Next earnings
- Nov 3 before open
- Shares outstanding
- 639.2M
Clarivate swing-trade checklist
Clarivate scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $1.61 is below the 50-day ($1.87) and 200-day ($2.34) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
64.3, Accumulation
Reading 64.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
30.0% below
Price is 30% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 2 open-market insider purchases.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−1.8% on average
From this point in the calendar, the next 20 trading days averaged −1.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Clarivate stock chart and price history
Clarivate closed at $1.61 on Oct 12, 2026, −55.4% over the past year, inside a 52-week range of $1.42 to $3.87.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −13.9%
- 3 months
- −30.6%
- 6 months
- −29.1%
- 1 year
- −55.4%
The full CLVT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CLVT in Gekko
Follow Clarivate through every session
Put CLVT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CLVT in GekkoFree for 7 days. No credit card required.
About Clarivate
Clarivate supplies structured data, analytics and software that help organizations find, protect and profit from scientific research, inventions and brand assets. It is widely recognized for its Web of Science suite, which includes tools such as InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons and Kopernio, used to support research work from planning through to publication and use.
Beyond the Web of Science offering, Clarivate serves pharmaceutical and biotech firms through products like Cortellis and Newport Integrity, which assist with market intelligence and competitive tracking around drug development. Its Derwent line, covering Derwent Innovation, Techstreet and IP Professional Services, helps clients assess novelty, check freedom to operate, pursue patents and track industry standards. CompuMark adds trademark search and monitoring, while MarkMonitor focuses on managing and protecting digital brand presence. Customers include government bodies, universities, life science companies and R&D organizations, with a footprint spanning the Americas, the Middle East, Africa, Europe and Asia Pacific.
Clarivate is headquartered in London, United Kingdom, and was previously known as Clarivate Analytics Plc before adopting its current name in May 2020. Its shares are listed on the NYSE under the ticker CLVT.
- Listed
- NYSE
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Website
- clarivate.com
Clarivate GekkoIndex: the smart money zone
Clarivate’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.3, in the Accumulation zone, down 11.5 points over five sessions.
64.3Accumulation
Down 11.5 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 80 | +2.5% | +10.1% | ||
| Accumulation (current zone) | 329 | −0.9% | −3.7% | ||
| Neutral | 261 | −1.9% | −8.0% | ||
| Distribution | 11 | −2.6% | −5.0% | ||
| Selling | 1 | Too few readings yet | |||
Average CLVT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the CLVT price, zone by zone.Track CLVT in Gekko
Is Clarivate stock overvalued? Gekko Fair Value
Clarivate trades 30.0% below Gekko Fair Value of $2.30, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Clarivate shares are worth, recalculated every trading day.
$2.30
Gekko Fair Value, Oct 9, 2026
30.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CLVT in Gekko
Clarivate insider and Congress trading
Insiders filed 2 open-market purchases in Clarivate worth $1.67M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CLVT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CLVT, plotted on the chart in Gekko.Open CLVT in Gekko
Buybacks
Clarivate has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.30M
- As a share of market cap
- 0.13%
- Trailing four quarters
- $144.4M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold CLVT.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Clarivate earnings: next date and track record
Clarivate reports on Nov 3, 2026, before the open (22 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 22 days away
- EPS estimate
- $0.18
- Revenue estimate
- $566.8M
6 of 8reports beat the EPS estimate
±17.1%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Clarivate reported Q2 2026 results with a mixed but constructive tone: revenue of $587M (H1 nearly $1.2B), organic ACV growth of 1.5%, adjusted diluted EPS of $0.19 (+$0.01 year-over-year) and expanded profit margin above 42%. The company recorded a $269M net loss driven entirely by a non-cash impairment tied to the announced agreement to divest the Life Sciences & Healthcare (LS&H) segment. Operating cash flow was $99M. Management emphasized progress against its value-creation plan (VCP): advancing an AI innovation roadmap (announcing Nexus Connect and IP-1), shifting from transactional to recurring revenue, disciplined cost management, and deleveraging the balance sheet. Segment-level notes: Academia & Government and Life Sciences & Healthcare delivered ~2% organic ACV growth; Intellectual Property’s recurring organic revenue was flat in Q2 with management expecting a return to growth in H2. Management announced Michael Easton as incoming CFO and reiterated focus on accelerating organic growth and improving free cash flow and profitability. Management expects an inflection in organic recurring revenue and ACV growth in the second half of the year and that transactional revenues will be down slightly year-over-year with improvement in H2. The announced LS&H divestiture is expected to close before year-end and management indicated no material MAC concerns. Q&A tone was generally confident and measured, with management providing clear, direct answers about renewal timing, transactional headwinds, and the path to subscription conversion.
- Guidance
- Qualitative/forward-looking guidance: Management expects organic recurring revenue and ACV to inflect and accelerate in the second half of 2026, anticipates a return to growth in the Intellectual Property segment in H2, and expects transactional revenue to be slightly down year-over-year for the full year with improvement in H2. The LS&H divestiture is expected to close before year-end. No new quantitative guidance (specific revenue/earnings targets) was provided on the call.
- Risks flagged
- Risks mentioned or implied: non-cash impairment tied to the LS&H divestiture; transactional revenue decline and the requirement to convert transactional streams to subscriptions; foreign-exchange headwinds impacting adjusted EBITDA; timing risks around renewals and sales cycles; reliance on successful execution of AI product commercialization and customer adoption; potential regulatory or closing risks around the divestiture (though management indicated customary approvals and no MAC concern).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | $0.17 est $0.14 | $587.3M est $589.7M | −16.3% |
| Apr 29, 2026 | $0.18 est $0.14 | $585.5M est $569.5M | +14.3% |
| Feb 24, 2026 | $0.20 est $0.17 | $617.0M est $604.8M | +36.9% |
| Oct 29, 2025 | $0.18 est $0.16 | $623.1M est $604.8M | −11.0% |
| Jul 30, 2025 | $0.18 est $0.18 | $621.4M est $570.4M | −9.0% |
| Apr 29, 2025 | $0.14 est $0.12 | $593.7M est $587.5M | +20.1% |
| Feb 19, 2025 | $0.21 est $0.20 | $663.0M est $601.2M | +0.2% |
| Nov 6, 2024 | $0.19 est $0.19 | $622.2M est $663.4M | −29.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Clarivate stock forecast and analyst price targets
Analysts’ average 12-month price target for Clarivate is $2.97, +84.3% from the last close, from 5 firms rating the stock in the last 90 days.
$2.97consensus 12-month target, +84.3% from the last close
Now $1.61Avg $2.97
Low $2High $5
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Jul 30 | RBC Capital | $3 | +86.3% |
| Jul 30 | Stifel Nicolaus | $5 | +210.6% |
| Jul 30 | Citi | $2.50 | +55.3% |
| Jul 30 | Barclays | $2 | +24.2% |
| Jul 29 | Goldman Sachs | $2.60 | +61.5% |
−3.7%average 20-day move after past Accumulation readings
−1.8%average move over the next 20 trading days in the last 5 years
±5.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Clarivate seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Clarivate averaged −1.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 2 of 5 |
| Next 10 trading days | +1.1% | 2 of 5 |
| Next 15 trading days | +1.8% | 2 of 5 |
| Next 20 trading days | −1.8% | 3 of 5 |
| Next 30 trading days | −2.2% | 2 of 5 |
For scale, CLVT’s typical 20-trading-day move in either direction is about 9.1%.
Clarivate market cap and key statistics
Clarivate’s market cap is $1.03B and revenue of $2.41B over the last twelve months.
Valuation
- Market cap
- $1.03B
- Forward P/E
- 2.6
- EPS, TTM
- −$0.52
- Gekko Fair Value
- $2.30
Trading
- Volume
- 2.04M
- Avg volume, 20 days
- 4.15M
- 52-week high
- $3.87
- 52-week low
- $1.42
- Shares outstanding
- 639.2M
Financials
- Revenue, TTM
- $2.41B
- Profit margin
- -13.8%
- Return on equity
- -7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.40
- Typical daily move
- ±5.7%
- Typical 20-day move
- ±9.1%
Clarivate stock news this week
Coverage of Clarivate this week reads neutral: 4 positive, 5 neutral and 1 negative headlines.
- Latham Advises on Financing for Altaris’ Completed Acquisition of Clarivate’s Life Sciences & Healthcare BusinessLatham & Watkins LLP, Oct 12
- Form 4 CLARIVATE PLC For: 9 October By Investing.comInvesting.com Nigeria, Oct 9
- Henry Levy Surrenders 263,576 Clarivate Shares for Tax Obligations Following RSU VestingKalkine Media, Oct 8
- Clarivate Divests Life Sciences Unit to Refocus CoreThe Globe and Mail, Oct 7
- Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic TransformationMorningstar, Oct 7
- Altaris Completes Acquisition of Clarivate’s Life Sciences & Healthcare BusinessClarivate, Oct 7
Clarivate peers
Clarivate’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Distribution | 25.9% above |
| CTASCintas | Neutral | 14.1% above |
| PYPLPayPal | Neutral | 0.8% below |
| XYZBlock | Neutral | 7.5% above |
| CPAYCorpay | Neutral | 17.5% below |
| FISVFiserv | Accumulation | 39.7% below |
A peer links to its own page where one exists.
Clarivate stock FAQ
What is Clarivate’s market cap?
Clarivate’s market cap is $1.03B at the Oct 12, 2026 close of $1.61, with 639.2M shares outstanding.
What is the Clarivate stock forecast?
The consensus analyst 12-month price target for Clarivate is $2.97, +84.3% from the last close. Of the 5 firms that rated the stock in the last 90 days, 1 rate it a buy, 3 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Clarivate stock overvalued or undervalued?
On Gekko’s estimate Clarivate is undervalued: the Oct 12, 2026 close of $1.61 is 30.0% below Gekko Fair Value of $2.30. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Clarivate report earnings next?
Clarivate is expected to report on Nov 3, 2026, before the market opens (22 days away). Analysts expect earnings of $0.18 per share on revenue of $566.8M. Clarivate beat the earnings estimate in 6 of its last 8 reports, moving 17.1% on average across the report.
What is Clarivate’s 52-week high and low?
Clarivate’s 52-week high is $3.87 and its 52-week low is $1.42; it closed at $1.61 on Oct 12, 2026, −55.4% over the past year. Over the last five years the shares peaked at $25.63 on Dec 13, 2021.
Is Clarivate stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and smart money), 1 as mixed (seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Clarivate the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.